ClinicalTrials.gg
CompletedNCT00734474Updated Apr 20, 2015Results posted

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

A Phase 2/3 interventional study of LY2189265 and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 99 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-20.

Sponsored by Eli Lilly and Company · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,202
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
3rd of 54
1,202 · median 159
Started
2008
with 2 others
Phase 2/3
Only one
of the 54
Registered
2nd of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 3rd largest by enrollment, is one of 3 that started in 2008, is the only one in phase 2/3, and was the 2nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is an adaptive dose finding study and a Phase 3 efficacy study to evaluate the effects of once weekly injection of LY2189265 compared to Sitagliptin on glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 52 weeks in participants with type 2 diabetes mellitus on Metformin.

Read the detailed description

This is a double blind study designed to select 1 or 2 LY2189265 doses for evaluation in Phase 3 studies (dose-finding portion) and to evaluate efficacy and safety of selected doses of LY2189265 in comparison to Sitagliptin (100 milligrams) up to 104 weeks and Placebo up to 26 weeks in participants with type 2 diabetes mellitus on Metformin (confirmatory, Phase 3 portion). The primary objective is to show non-inferiority of the higher LY2189265 dose (if 2 doses are selected) to Sitagliptin with respect to change in glycosylated hemoglobin (HbA1c) at 52 weeks. The final endpoint is 104 weeks.

Participants are randomized to receive Placebo, Sitagliptin, or 1 of 7 initial LY2189265 doses until a dose decision is made based on quantitative analysis of the benefits and risks of each LY2189265 dose. A clinical utility index (CUI) that applies predicted values for change from baseline in HbA1c at 12 months and change from baseline in weight, diastolic blood pressure, and pulse rate at 6 months for each LY2189265 dose will be used toward this end. After the dose decision, participants in the selected LY2189265 arms and the comparator arms (Sitagliptin and Placebo/Sitagliptin arms) will continue the study, and additional participants will be randomized to the selected and comparator arms. Regardless of the timing of randomization relative to the dose decision point, all participants in the selected and comparator arms are planned to receive treatment for 104 weeks; participants in the Placebo/Sitagliptin arm will receive Placebo treatment for 26 weeks followed by Sitagliptin 100 mg for 78 weeks for blinding purposes only, and participants in the selected and Sitagliptin arms will receive the same treatment for 104 weeks. All participants will remain blinded to their study treatment throughout the study. Participants in the non-selected arms will discontinue from the study after the dose decision

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes, type 2 diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes mellitus, type 2, for at least 6 months
  • Treatment regimens: diet and exercise, metformin as monotherapy or in combination with another oral antihyperglycemic medication (OAM), or another OAM as monotherapy. Must be able to tolerate metformin at a dose of at least 1500 milligrams (mg) daily for 6 weeks prior to randomization.
  • Glycosylated () value of ≥7.0% to ≤9.5%, except participants on diet and exercise therapy who must have had HbA1c value of >8.0% to ≤9.5%
  • (BMI) between 25 and 40 kilograms per meter squared (kg/m\^2), inclusive
  • Stable weight for 3 months prior to screening
  • Females of must test negative for pregnancy and agree to use a reliable method

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus, type 1
  • Use of a glucagon-like peptide-1 (GLP-1) analog (for example, exenatide) within 6 months prior to screening or are being treated with insulin
  • Gastric emptying abnormality, history of bariatric surgery, or chronic use of drugs that affect gastrointestinal motility
  • Use of medications to promote weight loss
  • Clinically-relevant cardiovascular event within 6 months prior to screening
  • Poorly controlled hypertension
  • (ECG) reading considered outside the normal limits or indicating cardiac disease
  • Liver disease, hepatitis, chronic pancreatitis, idiopathic acute pancreatitis, or (ALT) levels >3.0 times the
  • Serum creatinine ≥1.5 milligrams per deciliter (mg/dL) or a \<60 milliliters per minute (mL/minute)
  • Uncontrolled diabetes, defined as >2 episodes of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to study entry.
  • Uncontrolled endocrine or abnormality
  • History of a transplanted organ
  • Chronic use of systemic therapy
  • Active or untreated
  • Use of central nervous system (CNS) stimulants
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,202 participants (actual)

Study arms

  • Experimental
    3.0 mg LY2189265

    LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks

    Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin

  • Experimental
    2.0 mg LY2189265

    LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks

    Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin

  • Experimental
    1.5 mg LY2189265

    LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks

    Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin

  • Experimental
    1.0 mg LY2189265

    LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks

    Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin

  • Experimental
    0.75 mg LY2189265

    LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks

    Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin

  • Experimental
    0.5 mg LY2189265

    LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks

    Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin

  • Experimental
    0.25 mg LY2189265

    LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks Placebo: tablet, administered orally, once daily for up to 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks

    Drug: LY2189265 · Drug: Placebo tablet · Drug: Metformin

  • Active comparator
    Sitagliptin

    Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks

    Drug: Sitagliptin · Drug: Placebo solution · Drug: Metformin

  • Placebo comparator
    Placebo/Sitagliptin (Baseline Through 104 Weeks)

    Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks Placebo: tablet, administered orally, once daily for 26 weeks Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks

    Drug: Placebo solution · Drug: Placebo tablet · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Glycosylated Hemoglobin (HbA1c) Change From Baseline

    Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, 52 weeks

Secondary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point

    Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.

    Time frame: Baseline up to 27.4 weeks

  2. Glycosylated Hemoglobin (HbA1c) Change From Baseline

    Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, 26 weeks, 104 weeks

  3. Durability of Change From Baseline in Glycosylated Hemoglobin (HbA1c)

    Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 13, 26, 52, and 104 weeks

  4. Fasting Blood Glucose Change From Baseline

    Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 104 weeks

  5. Fasting Insulin Change From Baseline

    Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 104 weeks

  6. Change From Baseline in Body Weight at Dose Decision Point

    Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.

    Time frame: Baseline up to 27.4 weeks

  7. Body Weight Change From Baseline

    Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 104 weeks

  8. Durability of Change From Baseline Body Weight

    Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 13, 26, 52, and 104 weeks

  9. Waist Circumference Change From Baseline

    Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 104 weeks

  10. Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%

    The percentage of participants achieving HbA1c levels \<7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model.

    Time frame: Baseline, 26, 52, and 104 weeks

  11. Incidence of Hypoglycemic Episodes

    Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively.

    Time frame: Baseline through 26 and 104 weeks

  12. Rate of Hypoglycemic Episodes

    Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively.

    Time frame: Baseline through 26 and 104 weeks

  13. Beta Cell Function and Insulin Sensitivity (HOMA2)

    The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26, 52, and 104 weeks

  14. Number of Participants With Treatment-emergent Adverse Events at 26 Weeks

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks

  15. Number of Participants With Treatment-emergent Adverse Events at 52 Weeks

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  16. Number of Participants With Treatment-emergent Adverse Events at 104 Weeks

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 104 weeks

  17. Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 26 Weeks

    The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).

    Time frame: Baseline through 26 weeks

  18. Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 52 Weeks

    The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) .

    Time frame: Baseline through 52 weeks

  19. Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 104 Weeks

    The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).

    Time frame: Baseline through 104 weeks

  20. Number of Participants With Treatment-emergent Abnormal Lipid Tests

    The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], and triglycerides \[TG\]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively.

    Time frame: Baseline through 26 and 104 weeks

  21. Change From Baseline in Pulse Rate at Dose Decision Point

    Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.

    Time frame: Baseline up to 27.4 weeks

  22. Change From Baseline in Blood Pressure at Dose Decision Point

    Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks.

    Time frame: Baseline up to 27.4 weeks

  23. Change From Baseline in Pulse Rate

    Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate.

    Time frame: Baseline, 26 weeks, 104 weeks

  24. Change From Baseline in Blood Pressure

    Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks, 104 weeks

  25. Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia-corrected QT (QTcF) and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 weeks, 104 weeks

  26. Participant-reported Outcomes, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)

    The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants' quality of life. Items are scored on a 5-point numeric rating scale where 5 = "always true" and 1 = "never true". Items are summed into 6 scales (physical function \[11 items\], self-esteem \[7 items\], sexual life \[4 items\], public distress \[5 items\], work \[4 items\], and total score \[31 items\]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale.

    Time frame: Baseline, 52 weeks, and 104 weeks

  27. Participant-reported Outcomes, EQ-5D

    The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Baseline, 52 weeks, and 104 weeks

  28. Resource Utilization

    The number of visits to the emergency room (ER) is summarized cumulatively.

    Time frame: Baseline through 52 and 104 weeks

  29. Pharmacokinetics of LY2189265: Area Under the Concentration-Time Curve

    Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized.

    Time frame: Baseline through 52 weeks

  30. Antibodies to LY2189265

    The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized.

    Time frame: Baseline through 104 weeks

Other outcomes

  1. Number of Participants With Adjudicated Pancreatitis at 104 Weeks

    The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 104 weeks

  2. Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks

    Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 104 weeks

07

Results

Posted Jan 28, 2015

Participant flow

Participant flow — Overall Study
Milestone3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin
Started1530304103022524315177
Received at least 1 dose of study drug1530304103022524315177
Entered study before dose decision point153025102125244238
Completed up to dose decision point8252482121234234
Entered study after dose decision point00279028100273139
Completed 26-week visit00258226822270124
Completed 52-week visit00238024300238112
Completed0019201840018695
Not completed153011210118252412982
Withdrew: Entry criteria not met005031011
Withdrew: Lost to follow-up10130111094
Withdrew: Withdrawal by subject2118024203621
Withdrew: Physician decision0041110099
Withdrew: Adverse event4463164016539
Withdrew: Protocol violation004030031
Withdrew: Sponsor decision, arm discontinued825080212300
Withdrew: Sponsor decision000020000
Withdrew: Death001000021
Withdrew: Lack of efficacy004000046

Outcome measures

PrimaryGlycosylated Hemoglobin (HbA1c) Change From Baseline

Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, 52 weeks
Reported as:
Least squares mean · percentage of HbA1c
Glycosylated Hemoglobin (HbA1c) Change From Baseline
percentage of HbA1c1.5 mg LY21892650.75 mg LY2189265Sitagliptin
Glycosylated Hemoglobin (HbA1c) Change From Baseline-1.10 ± 0.06-0.87 ± 0.06-0.39 ± 0.06
Statistical analysis
  • 1.5 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.71 · 95% CI -0.87 to -0.55
  • 0.75 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.47 · 95% CI -0.63 to -0.31
  • 1.5 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.71 · 95% CI -0.87 to -0.55
  • 0.75 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (P-value is adjusted for multiplicity, based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.47 · 95% CI -0.63 to -0.31
SecondaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point

Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.

Time frame:
Baseline up to 27.4 weeks
Reported as:
Mean · percentage of HbA1c
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point
percentage of HbA1c3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point-1.09 ± 0.77-1.25 ± 0.68-1.49 ± 1.12-0.98 ± 0.47-1.02 ± 0.99-0.94 ± 0.65-0.70 ± 0.49-0.76 ± 0.86-0.06 ± 0.64
SecondaryGlycosylated Hemoglobin (HbA1c) Change From Baseline

Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, 26 weeks, 104 weeks
Reported as:
Least squares mean · percentage of HbA1c
Glycosylated Hemoglobin (HbA1c) Change From Baseline
percentage of HbA1c1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
26 Weeks-1.22 ± 0.05-1.01 ± 0.06-0.61 ± 0.050.03 ± 0.07
104 Weeks-0.99 ± 0.06-0.71 ± 0.07-0.32 ± 0.06NA ± NA
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · ANCOVA · p = <0.001 (Comparison at 26 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -1.26 · 95% CI -1.42 to -1.09
  • 0.75 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · ANCOVA · p = <0.001 (Comparison at 26 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -1.05 · 95% CI -1.21 to -0.88
  • Sitagliptin vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · ANCOVA · p = <0.001 (Comparison at 26 weeks. One-sided raw p-value with no adjustment for multiplicity.) · Ls mean difference: -0.64 · 95% CI -0.81 to -0.48
  • 1.5 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (Comparison at 104 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.67 · 95% CI -0.84 to -0.50
  • 0.75 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (Comparison at 104 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.39 · 95% CI -0.56 to -0.22
  • 1.5 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (Comparison at 104 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.67 · 95% CI -0.84 to -0.50
  • 0.75 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (Comparison at 104 weeks. P-value adjusted for multiplicity based on tree-gatekeeping strategy. To determine significance, p-value is compared to the family-wise 1-sided Type I error of 0.025. The confidence interval is not adjusted for multiplicity.) · Ls mean difference: -0.39 · 95% CI -0.56 to -0.22
SecondaryDurability of Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 13, 26, 52, and 104 weeks
Reported as:
Least squares mean · percentage of HbA1c
Durability of Change From Baseline in Glycosylated Hemoglobin (HbA1c)
percentage of HbA1c1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
26 Weeks Versus 13 Weeks (n=269, 269, 276, 136)-0.03 ± 0.040.02 ± 0.040.00 ± 0.04-0.14 ± 0.05
52 Weeks Versus 26 Weeks (n=245, 254, 250)0.14 ± 0.050.16 ± 0.050.24 ± 0.05NA ± NA
104 Weeks Versus 52 Weeks (n=194, 191, 190)0.13 ± 0.060.16 ± 0.060.09 ± 0.06NA ± NA
SecondaryFasting Blood Glucose Change From Baseline

Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 104 weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Fasting Blood Glucose Change From Baseline
millimoles per liter (mmol/L)1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
26 Weeks (n=265, 271, 276, 135)-2.38 ± 0.12-1.97 ± 0.12-0.97 ± 0.11-0.49 ± 0.16
52 Weeks (n=239, 247, 244)-2.38 ± 0.13-1.63 ± 0.13-0.90 ± 0.13NA ± NA
104 Weeks (n=190, 187, 181)-1.99 ± 0.15-1.39 ± 0.15-0.47 ± 0.15NA ± NA
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.89 · 95% CI -2.27 to -1.51Comparison at 26 weeks.
  • 0.75 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = <0.001 (Comparison at 26 weeks.) · Ls mean difference: -1.48 · 95% CI -1.85 to -1.10
  • Sitagliptin vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = 0.012 (Comparison at 26 weeks.) · Ls mean difference: -0.48 · 95% CI -0.86 to -0.11
  • 1.5 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = <0.001 (Comparison at 52 weeks.) · Ls mean difference: -1.47 · 95% CI -1.82 to -1.13
  • 0.75 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = <0.001 (Comparison at 52 weeks.) · Ls mean difference: -0.73 · 95% CI -1.07 to -0.39
  • 1.5 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = <0.001 (Comparison at 104 weeks.) · Ls mean difference: -1.51 · 95% CI -1.93 to -1.10
  • 0.75 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = <0.001 (Comparison at 104 weeks.) · Ls mean difference: -0.92 · 95% CI -1.33 to -0.51
SecondaryFasting Insulin Change From Baseline

Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 104 weeks
Reported as:
Least squares mean · picomoles per liter (pmol/L)
Fasting Insulin Change From Baseline
picomoles per liter (pmol/L)1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
26 Weeks (n=238, 249, 230, 115)11.59 ± 6.5710.15 ± 6.518.48 ± 6.68-6.92 ± 9.24
52 Weeks (n=207, 218, 200)10.57 ± 5.9512.95 ± 5.884.18 ± 6.01NA ± NA
104 Weeks (n=187, 200, 183)11.36 ± 7.5821.56 ± 7.400.29 ± 7.64NA ± NA
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = 0.095 (Comparison at 26 weeks.) · Ls mean difference: 18.51 · 95% CI -3.25 to 40.28
  • 0.75 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = 0.121 (Comparison at 26 weeks.) · Ls mean difference: 17.08 · 95% CI -4.54 to 38.69
  • Sitagliptin vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = 0.167 (Comparison at 26 weeks.) · Ls mean difference: 15.41 · 95% CI -6.47 to 37.29
  • 1.5 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = 0.430 (Comparison at 52 weeks.) · Ls mean difference: 6.38 · 95% CI -9.49 to 22.26
  • 0.75 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = 0.273 (Comparison at 52 weeks.) · Ls mean difference: 8.77 · 95% CI -6.94 to 24.47
  • 1.5 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = 0.291 (Comparison at 104 weeks.) · Ls mean difference: 11.07 · 95% CI -9.49 to 31.64
  • 0.75 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = 0.039 (Comparison at 104 weeks.) · Ls mean difference: 21.28 · 95% CI 1.03 to 41.53
SecondaryChange From Baseline in Body Weight at Dose Decision Point

Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.

Time frame:
Baseline up to 27.4 weeks
Reported as:
Mean · kilograms (kg)
Change From Baseline in Body Weight at Dose Decision Point
kilograms (kg)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Change From Baseline in Body Weight at Dose Decision Point-3.32 ± 3.37-2.15 ± 1.97-2.12 ± 1.93-2.23 ± 1.63-1.17 ± 2.30-1.53 ± 1.88-0.85 ± 1.47-0.43 ± 1.78-0.56 ± 1.69
SecondaryBody Weight Change From Baseline

Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 104 weeks
Reported as:
Least squares mean · kilograms (kg)
Body Weight Change From Baseline
kilograms (kg)1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
26 Weeks-3.18 ± 0.18-2.63 ± 0.19-1.46 ± 0.18-1.47 ± 0.24
52 Weeks-3.03 ± 0.22-2.60 ± 0.23-1.53 ± 0.22NA ± NA
104 Weeks-2.88 ± 0.25-2.39 ± 0.26-1.75 ± 0.25NA ± NA
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · ANCOVA · p = <0.001 (Comparison at 26 weeks.) · Ls mean difference: -1.70 · 95% CI -2.27 to -1.14
  • 0.75 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · ANCOVA · p = <0.001 (Comparison at 26 weeks.) · Ls mean difference: -1.16 · 95% CI -1.73 to -0.60
  • Sitagliptin vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · ANCOVA · p = 0.953 (Comparison at 26 weeks.) · Ls mean difference: 0.02 · 95% CI -0.54 to 0.58
  • 1.5 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (Comparison at 52 weeks.) · Ls mean difference: -1.50 · 95% CI -2.08 to -0.92
  • 0.75 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (Comparison at 52 weeks.) · Ls mean difference: -1.07 · 95% CI -1.65 to -0.48
  • 1.5 mg LY2189265 vs Sitagliptin · ANCOVA · p = <0.001 (Comparison at 104 weeks.) · Ls mean difference: -1.14 · 95% CI -1.78 to -0.49
  • 0.75 mg LY2189265 vs Sitagliptin · ANCOVA · p = 0.054 (Comparison at 104 weeks.) · Ls mean difference: -0.64 · 95% CI -1.29 to 0.01
SecondaryDurability of Change From Baseline Body Weight

Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 13, 26, 52, and 104 weeks
Reported as:
Least squares mean · kilograms (kg)
Durability of Change From Baseline Body Weight
kilograms (kg)1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
26 Weeks Versus 13 Weeks (n=271, 278, 282, 138)-0.53 ± 0.14-0.57 ± 0.14-0.42 ± 0.13-0.37 ± 0.18
52 Weeks Versus 26 Weeks (n=246, 255, 253)0.17 ± 0.180.06 ± 0.18-0.04 ± 0.18NA ± NA
104 Weeks Versus 26 Weeks (n=197, 192, 191)0.42 ± 0.230.32 ± 0.24-0.39 ± 0.23NA ± NA
SecondaryWaist Circumference Change From Baseline

Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 104 weeks
Reported as:
Least squares mean · centimeters (cm)
Waist Circumference Change From Baseline
centimeters (cm)1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
26 Weeks (n=266, 273, 277, 138)-2.89 ± 0.24-1.78 ± 0.24-1.45 ± 0.24-1.20 ± 0.32
52 Weeks (n=238, 250, 247)-2.91 ± 0.29-2.05 ± 0.29-1.45 ± 0.29NA ± NA
104 Weeks (n=192, 189, 188)-2.57 ± 0.35-1.75 ± 0.35-1.20 ± 0.35NA ± NA
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = <0.001 (Comparison at 26 weeks.) · Ls mean difference: -1.69 · 95% CI -2.45 to -0.93
  • 0.75 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = 0.133 (Comparison at 26 weeks.) · Ls mean difference: -0.58 · 95% CI -1.34 to 0.18
  • Sitagliptin vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Mixed Models Analysis · p = 0.512 (Comparison at 26 weeks.) · Ls mean difference: -0.25 · 95% CI -1.01 to 0.50
  • 1.5 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = <0.001 (Comparison at 52 weeks.) · Ls mean difference: -1.46 · 95% CI -2.23 to -0.69
  • 0.75 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = 0.128 (Comparison at 52 weeks.) · Ls mean difference: -0.59 · 95% CI -1.36 to 0.17
  • 1.5 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = 0.005 (Comparison at 104 weeks.) · Ls mean difference: -1.36 · 95% CI -2.30 to -0.42
  • 0.75 mg LY2189265 vs Sitagliptin · Mixed Models Analysis · p = 0.256 (Comparison at 104 weeks.) · Ls mean difference: -0.54 · 95% CI -1.48 to 0.40
SecondaryPercentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%

The percentage of participants achieving HbA1c levels \<7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model.

Time frame:
Baseline, 26, 52, and 104 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%
percentage of participants1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
<7.0% at 26 Weeks60.955.237.821.0
<7.0% at 52 Weeks57.648.833.0NA
<7.0% at 104 Weeks54.344.831.1NA
≤6.5% at 26 Weeks46.731.021.812.5
≤6.5% at 52 Weeks41.729.019.2NA
≤6.5% at 104 Weeks39.124.214.1NA
Statistical analysis
  • 1.5 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Regression, Logistic · p = <0.001 (Comparison of HbA1c \<7.0% at 26 weeks.) · Odds ratio (or): 11.3 · 95% CI 6.8 to 18.8
  • 0.75 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Regression, Logistic · p = <0.001 (Comparison of HbA1c \<7.0% at 26 weeks.) · Odds ratio (or): 8.6 · 95% CI 5.2 to 14.3
  • Sitagliptin vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Regression, Logistic · p = <0.001 (Comparison of HbA1c \<7.0% at 26 weeks.) · Odds ratio (or): 3.0 · 95% CI 1.8 to 4.8
  • 1.5 mg LY2189265 vs Sitagliptin · Regression, Logistic · p = <0.001 (Comparison of HbA1c \<7.0% at 52 weeks.) · Odds ratio (or): 4.0 · 95% CI 2.7 to 5.9
  • 0.75 mg LY2189265 vs Sitagliptin · Regression, Logistic · p = <0.001 (Comparison of HbA1c \<7.0% at 52 weeks.) · Odds ratio (or): 2.7 · 95% CI 1.8 to 3.9
  • 1.5 mg LY2189265 vs Sitagliptin · Regression, Logistic · p = <0.001 (Comparison of HbA1c \<7.0% at 104 weeks.) · Odds ratio (or): 3.4 · 95% CI 2.4 to 5.0
  • 0.75 mg LY2189265 vs Sitagliptin · Regression, Logistic · p = <0.001 (Comparison of HbA1c \<7.0% at 104 weeks.) · Odds ratio (or): 2.3 · 95% CI 1.6 to 3.3
  • 1.5 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Regression, Logistic · p = <0.001 (Comparison of HbA1c ≤6.5% at 26 weeks.) · Odds ratio (or): 11.5 · 95% CI 6.5 to 20.4
  • 0.75 mg LY2189265 vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Regression, Logistic · p = <0.001 (Comparison of HbA1c ≤6.5% at 26 weeks.) · Odds ratio (or): 5.0 · 95% CI 2.8 to 8.8
  • Sitagliptin vs Placebo/Sitagliptin (Baseline Through 26 Weeks) · Regression, Logistic · p = 0.005 (Comparison of HbA1c ≤6.5 at 26 weeks.) · Odds ratio (or): 2.3 · 95% CI 1.3 to 4.1
  • 1.5 mg LY2189265 vs Sitagliptin · Regression, Logistic · p = <0.001 (Comparison of HbA1c ≤6.5% at 52 weeks.) · Odds ratio (or): 4.4 · 95% CI 2.9 to 6.8
  • 0.75 mg LY2189265 vs Sitagliptin · Regression, Logistic · p = <0.001 (Comparison of HbA1c ≤6.5% at 52 weeks.) · Odds ratio (or): 2.3 · 95% CI 1.5 to 3.5
  • 1.5 mg LY2189265 vs Sitagliptin · Regression, Logistic · p = <0.001 (Comparison of HbA1c ≤6.5% at 104 weeks.) · Odds ratio (or): 5.2 · 95% CI 3.4 to 7.9
  • 0.75 mg LY2189265 vs Sitagliptin · Regression, Logistic · p = <0.001 (Comparison of HbA1c ≤6.5% at 104 weeks.) · Odds ratio (or): 2.4 · 95% CI 1.5 to 3.7
SecondaryIncidence of Hypoglycemic Episodes

Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively.

Time frame:
Baseline through 26 and 104 weeks
Reported as:
Number · participants
Incidence of Hypoglycemic Episodes
participants1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Severe HE, 26 Weeks0000
Severe HE, 104 Weeks000NA
Documented Symptomatic HE, 26 Weeks178102
Documented Symptomatic HE, 104 Weeks331918NA
Asymptomatic HE, 26 Weeks5500
Asymptomatic HE, 104 Weeks993NA
Nocturnal HE, 26 Weeks7520
Nocturnal HE, 104 Weeks141310NA
Probable HE, 26 Weeks5020
Probable HE, 104 Weeks626NA
SecondaryRate of Hypoglycemic Episodes

Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively.

Time frame:
Baseline through 26 and 104 weeks
Reported as:
Mean · episodes per participant per year
Rate of Hypoglycemic Episodes
episodes per participant per year1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Severe HE, 26 Weeks0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Severe HE, 104 Weeks0.0 ± 0.00.0 ± 0.00.0 ± 0.0NA ± NA
Documented Symptomatic HE, 26 Weeks0.3 ± 1.50.1 ± 0.90.1 ± 0.70.1 ± 0.9
Documented Symptomatic HE, 104 Weeks0.2 ± 0.90.2 ± 1.90.2 ± 1.4NA ± NA
Asymptomatic HE, 26 Weeks0.1 ± 0.80.1 ± 0.50.0 ± 0.00.0 ± 0.0
Asymptomatic HE, 104 Weeks0.1 ± 0.40.0 ± 0.20.0 ± 0.1NA ± NA
Nocturnal HE, 26 Weeks0.1 ± 0.90.1 ± 0.60.0 ± 0.40.0 ± 0.0
Nocturnal HE, 104 Weeks0.1 ± 0.50.0 ± 0.20.1 ± 0.5NA ± NA
Probable Symptomatic HE, 26 Weeks0.0 ± 0.40.0 ± 0.00.0 ± 0.20.0 ± 0.0
Probable Symptomatic HE, 104 Weeks0.0 ± 0.10.0 ± 0.00.0 ± 0.1NA ± NA
SecondaryBeta Cell Function and Insulin Sensitivity (HOMA2)

The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26, 52, and 104 weeks
Reported as:
Least squares mean · HOMA2-%
Beta Cell Function and Insulin Sensitivity (HOMA2)
HOMA2-%1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
HOMA2-%B, 26 Weeks (n=206, 226, 206, 84)32.28 ± 2.6726.98 ± 2.6010.81 ± 2.661.60 ± 4.02
HOMA2-%B, 52 Weeks (n=188, 198, 180)33.57 ± 2.5122.30 ± 2.476.66 ± 2.53NA ± NA
HOMA2-%B, 104 Weeks (n=148, 154, 134)30.89 ± 3.0519.11 ± 3.001.47 ± 3.15NA ± NA
HOMA2-%S, 26 Weeks (n=206, 226, 206, 84)5.75 ± 2.340.78 ± 2.282.29 ± 2.339.82 ± 3.50
HOMA2-%S, 52 Weeks (n=188, 198, 180)4.69 ± 2.352.28 ± 2.324.25 ± 2.37NA ± NA
HOMA2-%S, 104 Weeks (n=148, 154, 134)3.82 ± 3.00-0.12 ± 2.955.61 ± 3.11NA ± NA
SecondaryNumber of Participants With Treatment-emergent Adverse Events at 26 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events at 26 Weeks
participants1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Number of Participants With Treatment-emergent Adverse Events at 26 Weeks208204185111
SecondaryNumber of Participants With Treatment-emergent Adverse Events at 52 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events at 52 Weeks
participants3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265Sitagliptin
Number of Participants With Treatment-emergent Adverse Events at 52 Weeks92023382311510219
SecondaryNumber of Participants With Treatment-emergent Adverse Events at 104 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 104 weeks
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events at 104 Weeks
participants1.5 mg LY21892650.75 mg LY2189265Sitagliptin
Number of Participants With Treatment-emergent Adverse Events at 104 Weeks259255242
SecondaryNumber of Participants With Treatment-emergent Abnormal Laboratory Tests at 26 Weeks

The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).

Time frame:
Baseline through 26 weeks
Reported as:
Number · participants
Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 26 Weeks
participants1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Alkaline Phosphatase (n=276, 258, 281, 162)93123
ALT/SGPT (n=232, 237, 244, 128)1824258
Amylase Pancreatic, High (n=283, 277, 295, 160)54554218
Amylase Total (n=266, 265, 277, 143)33332713
AST/SGOT (n=273, 269, 284, 148)1412187
Basophils, High (n=268, 259, 278, 163)1010
Basophils, Low (n=269, 259, 278, 163)0000
Bilirubin Direct, High (n=295, 291, 307, 171)1112
Bilirubin Total, High (n=295, 290, 305, 168)2441
Calcitonin, High (n=226, 233, 230, 113)1220
Chloride, High (n=299, 293, 310, 174)0100
Chloride, Low (n=299, 293, 308, 174)1211
CPK, High (n=273, 262, 276, 1562920307
Creatinine, High (n=294, 285, 303, 172)71055
Creatinine Clearance, High (n=164, 186, 180, 107)17282625
Creatinine Clearance, Low (n=292, 278,303,168)1117126
Eosinophils, High (n=258, 256, 275, 157)41162
Eosinophils, Low (n=269, 259, 278, 163)0000
Erythrocyte Count, High (n=279, 272, 287, 164)1100
Erythrocyte Count, Low (n=274, 268, 280, 161)12773
GGT, High (n=234, 240, 245, 144)9112310
Hematocrit, High (n=273, 265, 279, 161)1112
Hematocrit, Low (n=256, 242, 259, 157)131065
Hemoglobin, High (n=278, 271, 289, 164)1112
Hemoglobin, Low (n=262, 249, 265, 162)131653
Leukocyte Count, High (n=272, 265, 286, 165)3610
Leukocyte Count, Low (n=272, 262, 280, 165)2341
Lipase, High (n=255, 248, 269, 147)109929737
Lymphocytes, High (n=249, 253, 269, 161)5963
Lymphocytes, Low (n=265, 258, 273, 159)3342
MCHC, High (n=274, 265, 280, 163)0000
MCHC, Low (n=273, 263, 279, 163)0200
MCV, High (n=261, 248, 263, 156)1912145
MCV, Low (n=264, 252, 275, 162)3220
Monocytes, High (n=266, 258, 274, 163)1031
Monocytes, Low (n=265, 255, 274, 158)65810
Neutrophils, High (n=264, 255, 276, 161)4531
Neutrophils, Low (n=263, 251, 271, 162)2121
Platelet Count, High (n=265, 260, 281, 160)0010
Platelet Count, Low (n=262, 252, 269, 154)2363
Potassium, High (n=297, 291, 307, 172)7254
Potassium, Low (n=298, 293, 308, 169)4631
Sodium, High (n=291, 291, 307, 170)3444
Sodium, Low (n=298, 292, 305, 174)2141
Urea Nitrogen, High (n=287, 282, 305, 169)1117135
UMCR, High (n=217, 204, 232, 130)189135
SecondaryNumber of Participants With Treatment-emergent Abnormal Laboratory Tests at 52 Weeks

The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) .

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants
Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 52 Weeks
participants1.5 mg LY21892650.75 mg LY2189265Sitagliptin
Alkaline Phosphatase, High (n=276, 258, 281)10616
ALT/SGPT, High (n=232, 237, 244)252728
Amylase Pancreatic, High (n=283, 277, 295)677055
Amylase Total, High (n=266, 265, 277)384236
AST/SGOT, High (n=273, 269, 284)151925
Basophils, High (n=276, 268, 287)101
Basophils, Low (n=277, 268, 287)000
Bilirubin Direct, High (n=295, 291, 307)112
Bilirubin Total, High (n=295, 290, 305)265
Calcitonin, High (n=233, 239, 235)422
Chloride, High (n=299, 293, 310)010
Chloride, Low (n=299, 293, 308)122
CPK, High (n=273, 262, 276)382843
Creatinine, High (n=294, 285, 303)9106
Creatinine Clearance, High (n=164, 186, 180)233029
Creatinine Clearance, Low (n=292, 278, 303)182015
Eosinophils, High (n=265, 265, 283)111410
Eosinophils, Low (n=277, 268, 287)000
Erythrocyte Count, High (n=283, 276, 292)311
Erythrocyte Count, Low (n=278, 272, 285)15911
GGT, High (n=234, 240, 245)101434
Hematocrit, High (n=280, 274, 290)322
Hematocrit, Low (n=262, 251, 269)211311
Hemoglobin, High (n=282, 275, 294)311
Hemoglobin, Low (n=265, 253, 269)211911
Leukocyte Count, High (n=277, 270, 292)763
Leukocyte Count, Low (n=277, 267, 284)539
Lipase, High (n=255, 248, 269)124111110
Lymphocytes, High (n=257, 262, 278)121511
Lymphocytes, Low (n=273, 266, 280)4411
MCHC, High (n=281, 274, 291)000
MCHC, Low (n=280, 272, 290)233
MCV, High (n=267, 256, 273)251819
MCV, Low (n=270, 261, 286)324
Monocytes, High (n=274, 267, 283)105
Monocytes, Low (n=271, 264, 282)8915
Neutrophils, High (n=272, 263, 285)877
Neutrophils, Low (n=271, 260, 279)626
Platelet Count, High (n=272, 267, 287)022
Platelet Count, Low (n=269, 259, 275)458
Potassium, High (n=297, 291, 307)1055
Potassium, Low (n=298, 293, 308)675
Sodium, High (n=291, 291, 307)584
Sodium, Low (n=298, 292, 305)314
Urea Nitrogen, High (n=287, 282, 305)141921
UMCR, High (n=223, 212, 238)332118
SecondaryNumber of Participants With Treatment-emergent Abnormal Laboratory Tests at 104 Weeks

The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR).

Time frame:
Baseline through 104 weeks
Reported as:
Number · participants
Number of Participants With Treatment-emergent Abnormal Laboratory Tests at 104 Weeks
participants1.5 mg LY21892650.75 mg LY2189265Sitagliptin
Alkaline Phosphate, High (n=276, 258, 281)131120
ALT/SGPT, High (n=232, 237, 244)293739
Amylase Pancreatic, High (n=283, 277, 295)817861
Amylase Total, High (n=266, 265, 277)445543
AST/SGOT, High (n=273, 269, 284)212736
Basophils, High (n=276, 268, 288)101
Basophils, Low (n=277, 268, 288)000
Bilirubin Direct, High (n=295, 291, 307)213
Bilirubin Total, High (n=295, 290, 305)386
Calcitonin, High (n=233, 239, 235)534
Chloride, High (n=299, 293, 310)021
Chloride, Low (n=299, 293, 308)323
CPK, High (n=273, 262, 276)524154
Creatinine, High (n=294, 285, 303)11169
Creatinine Clearance, High (n=164, 186, 180)263234
Creatinine Clearance, Low (n=292, 278, 303)242520
Eosinophils, High (n=265, 265, 284)122214
Eosinophils, Low (n=277, 268, 288)000
Erythrocyte Count, High (n=283, 276, 292)321
Erythrocyte Count, Low (n=278, 272, 285)181419
GGT, High (n=234, 240, 245)162445
Hematocrit, High (n=280, 274, 290)363
Hematocrit, Low (n=262, 251, 269)302429
Hemoglobin, High (n=282, 275, 294)432
Hemoglobin, Low (n=265, 253, 269)302825
Leukocyte Count, High (n=277, 270, 292)1398
Leukocyte Count, Low (n=277, 267, 284)9714
Lipase, High (n=255, 248, 269)142132126
Lymphocytes, High (n=257, 262, 279)192021
Lymphocytes, Low (n=273, 266, 281)5912
MCHC, High (n=281, 274, 291)000
MCHC, Low (n=280, 272, 290)545
MCV, High (n=267, 256, 273)392525
MCV, Low (n=270, 261, 286)934
Monocytes, High (n=274, 267, 284)3111
Monocytes, Low (n=271, 264, 283)101417
Neutrophils, High (n=272, 263, 286)151213
Neutrophils, Low (n=271, 260, 280)10610
Platelet Count, High (n=273, 268, 287)233
Platelet Count, Low (n=270, 260, 275)878
Potassium, High (n=297, 291, 307)1498
Potassium, Low (n=298, 293, 308)885
Sodium, High (n=291, 291, 307)10106
Sodium, Low (n=298, 292, 305)515
Urea Nitrogen, High (n=287, 282, 305)172929
UMCR, High (n=223, 212, 239)382730
SecondaryNumber of Participants With Treatment-emergent Abnormal Lipid Tests

The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol \[HDL-C\], low density lipoprotein cholesterol \[LDL-C\], and triglycerides \[TG\]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively.

Time frame:
Baseline through 26 and 104 weeks
Reported as:
Number · participants
Number of Participants With Treatment-emergent Abnormal Lipid Tests
participants1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Cholesterol, High, 26 Weeks (n=144, 158, 139, 58)1621208
Cholesterol, High, 104 Weeks (n=151, 164, 146)342934NA
HDL-C, High, 26 Weeks (n=197, 201, 189, 78)1000
HDL-C, Low, 26 Weeks (n=127, 137, 129, 52)91381
HDL-C, High, 104 Weeks (n=206, 212, 199)212NA
HDL-C, Low, 104 Weeks (n=134, 143, 138)132013NA
LDL-C, High, 26 Weeks (n=155, 163, 150, 61)1511197
LDL-C, High, 104 Weeks (n=163, 170, 157)312329NA
TG, High, 26 Weeks (n=163, 174, 156, 64)613102
TG, High, 104 Weeks (n=170, 183, 166)132215NA
SecondaryChange From Baseline in Pulse Rate at Dose Decision Point

Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks.

Time frame:
Baseline up to 27.4 weeks
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Pulse Rate at Dose Decision Point
beats per minute (bpm)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Change From Baseline in Pulse Rate at Dose Decision Point6.63 ± 7.283.43 ± 10.142.39 ± 7.883.34 ± 9.88-1.63 ± 8.031.91 ± 6.181.05 ± 9.44-0.16 ± 8.071.81 ± 7.90
SecondaryChange From Baseline in Blood Pressure at Dose Decision Point

Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks.

Time frame:
Baseline up to 27.4 weeks
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Blood Pressure at Dose Decision Point
millimeters of mercury (mmHg)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Sitting SBP-8.85 ± 12.92-4.63 ± 15.28-4.77 ± 11.37-2.00 ± 9.94-6.21 ± 19.130.40 ± 11.511.67 ± 10.18-2.16 ± 10.62-0.61 ± 14.75
Sitting DBP-1.21 ± 7.47-1.17 ± 6.32-1.20 ± 4.67-0.08 ± 8.00-3.18 ± 10.13-0.75 ± 7.991.28 ± 4.06-1.11 ± 6.65-0.22 ± 7.94
SecondaryChange From Baseline in Pulse Rate

Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate.

Time frame:
Baseline, 26 weeks, 104 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline in Pulse Rate
beats per minute (bpm)1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Sitting, 26 Weeks (n=271, 278, 283, 138)2.57 ± 0.471.90 ± 0.47-0.11 ± 0.46-0.22 ± 0.65
Sitting, 104 Weeks (n=197, 192, 191)2.28 ± 0.532.77 ± 0.54-0.78 ± 0.53NA ± NA
Standing, 26 Weeks (n=271, 277, 281, 138)3.24 ± 0.522.00 ± 0.52-0.24 ± 0.51-0.17 ± 0.71
Standing, 104 Weeks (n=197, 192, 191)2.26 ± 0.632.50 ± 0.64-1.06 ± 0.63NA ± NA
SecondaryChange From Baseline in Blood Pressure

Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks, 104 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Blood Pressure
millimeters of mercury (mmHg)1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
Sitting SBP, 26 Weeks (n=271, 278, 283, 138)-1.73 ± 0.67-1.40 ± 0.67-1.94 ± 0.661.12 ± 0.92
Sitting SBP, 104 Weeks (n=197, 192, 191)-0.07 ± 0.811.28 ± 0.820.02 ± 0.82NA ± NA
Sitting DBP, 26 Weeks (n=271, 278, 283, 138)-0.43 ± 0.43-0.20 ± 0.43-1.06 ± 0.420.68 ± 0.58
Sitting DBP, 104 Weeks (n=197, 192, 191)0.38 ± 0.521.40 ± 0.52-0.36 ± 0.52NA ± NA
Standing SBP, 26 Weeks (n=271, 277, 281, 138)-1.53 ± 0.76-1.72 ± 0.76-2.54 ± 0.740.26 ± 1.04
Standing SBP, 104 Weeks (n=197, 192, 191)-1.30 ± 0.920.17 ± 0.93-1.20 ± 0.92NA ± NA
Standing DBP, 26 Weeks (n=271, 277, 281, 138)-0.11 ± 0.480.03 ± 0.48-1.36 ± 0.47-0.52 ± 0.66
Standing DBP, 104 Weeks (n=197, 192, 191)-0.23 ± 0.570.36 ± 0.58-0.67 ± 0.58NA ± NA
SecondaryChange From Baseline in Electrocardiogram (ECG) Parameters, Fridericia-corrected QT (QTcF) and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 weeks, 104 weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia-corrected QT (QTcF) and PR Interval
milliseconds (msec)1.5 mg LY21892650.75 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)
PR Interval, 26 Weeks (n=256, 261, 268, 132)2.94 ± 0.661.60 ± 0.660.42 ± 0.652.24 ± 0.89
PR Interval, 104 Weeks (n=168, 170, 167)4.59 ± 0.903.06 ± 0.903.19 ± 0.90NA ± NA
QTcF Interval, 26 Weeks (n=258, 262, 268, 132)-3.86 ± 0.75-2.44 ± 0.75-1.31 ± 0.731.76 ± 1.02
QTcF Interval, 104 Weeks (n=169, 170, 168)-2.71 ± 0.84-2.49 ± 0.84-0.02 ± 0.83NA ± NA
SecondaryParticipant-reported Outcomes, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)

The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants' quality of life. Items are scored on a 5-point numeric rating scale where 5 = "always true" and 1 = "never true". Items are summed into 6 scales (physical function \[11 items\], self-esteem \[7 items\], sexual life \[4 items\], public distress \[5 items\], work \[4 items\], and total score \[31 items\]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale.

Time frame:
Baseline, 52 weeks, and 104 weeks
Reported as:
Mean · units on a scale
Participant-reported Outcomes, Impact of Weight on Quality of Life-Lite (IWQoL-Lite)
units on a scale1.5 mg LY21892650.75 mg LY2189265Sitagliptin
Total Score, Baseline (n=285, 284, 300)83.41 ± 16.03182.55 ± 16.95283.97 ± 16.514
Total Score, 52 Weeks (n=237, 252, 247)86.92 ± 14.97286.31 ± 14.67386.25 ± 15.628
Total Score, 104 Weeks (n=190, 190, 185)88.08 ± 15.55587.47 ± 15.18386.93 ± 16.304
SecondaryParticipant-reported Outcomes, EQ-5D

The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Baseline, 52 weeks, and 104 weeks
Reported as:
Mean · units on a scale
Participant-reported Outcomes, EQ-5D
units on a scale1.5 mg LY21892650.75 mg LY2189265Sitagliptin
EQ-5D, UK, Baseline (n=285, 281, 300)0.80 ± 0.2220.82 ± 0.2230.84 ± 0.216
EQ-5D, UK, 52 Weeks (n=237, 250, 244)0.83 ± 0.2110.84 ± 0.2080.85 ± 0.210
EQ-5D, UK, 104 Weeks (n=189, 190, 185)0.84 ± 0.2030.86 ± 0.1840.86 ± 0.198
VAS, Baseline (n=285, 284, 301)75.57 ± 15.79875.35 ± 16.00176.85 ± 15.363
VAS, 52 Weeks (n=238, 251, 245)78.93 ± 13.35278.22 ± 13.83978.79 ± 14.567
VAS, 104 Weeks (n=189, 190, 185)79.66 ± 13.82078.52 ± 14.11481.34 ± 13.708
SecondaryResource Utilization

The number of visits to the emergency room (ER) is summarized cumulatively.

Time frame:
Baseline through 52 and 104 weeks
Reported as:
Number · events
Resource Utilization
events1.5 mg LY21892650.75 mg LY2189265Sitagliptin
52 WeeksNANANA
104 WeeksNANANA
SecondaryPharmacokinetics of LY2189265: Area Under the Concentration-Time Curve

Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized.

Time frame:
Baseline through 52 weeks
Reported as:
Mean · nanograms times hours per milliliter
Pharmacokinetics of LY2189265: Area Under the Concentration-Time Curve
nanograms times hours per milliliter1.5 mg LY21892650.75 mg LY2189265
Pharmacokinetics of LY2189265: Area Under the Concentration-Time Curve13378 ± 61007246 ± 3304
SecondaryAntibodies to LY2189265

The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized.

Time frame:
Baseline through 104 weeks
Reported as:
Number · participants
Antibodies to LY2189265
participantsLY2189265
Antibodies to LY21892659
Other pre-specifiedNumber of Participants With Adjudicated Pancreatitis at 104 Weeks

The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 104 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis at 104 Weeks
participants3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)Placebo/Sitagliptin (26 Weeks Through 104 Weeks)
Number of Participants With Adjudicated Pancreatitis at 104 Weeks0000000201
Other pre-specifiedNumber of Participants With Adjudicated Cardiovascular Events at 104 Weeks

Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 104 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Cardiovascular Events at 104 Weeks
participants3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 26 Weeks)Placebo/Sitagliptin (26 Weeks Through 104 Weeks)
Participants With Any CV Event0060400503
Participants With a Fatal CV Event0010000101
Participants With a Non-fatal CV Event0060400402

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3.0 mg LY2189265—1/15 (6.7%)9/15 (60%)
2.0 mg LY2189265—1/30 (3.3%)20/30 (66.7%)
1.5 mg LY2189265—36/304 (11.8%)252/304 (82.9%)
1.0 mg LY2189265—0/10 (0%)8/10 (80%)
0.75 mg LY2189265—23/302 (7.6%)255/302 (84.4%)
0.5 mg LY2189265—1/25 (4%)15/25 (60%)
0.25 mg LY2189265—0/24 (0%)10/24 (41.7%)
Sitagliptin—32/315 (10.2%)239/315 (75.9%)
Placebo/Sitagliptin (Baseline Through 104 Weeks)—17/177 (9.6%)138/177 (78%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
Event3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 104 Weeks)
GastroenteritisInfections and infestations1/150/300/3040/100/3020/250/241/3150/177
PneumoniaInfections and infestations0/150/300/3040/100/3021/250/242/3150/177
Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/301/3040/100/3020/250/240/3150/177
Cervical dysplasiaReproductive system and breast disorders0/100/220/1580/70/1680/120/150/1641/87
Myocardial infarctionCardiac disorders0/150/302/3040/100/3020/250/241/3152/177
Blood calcitonin increasedInvestigations0/150/300/3040/103/3020/250/240/3150/177
Prostatic adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50/81/1460/31/1340/130/90/1510/90
Urinary tract infectionInfections and infestations0/150/300/3040/102/3020/250/240/3150/177
FallInjury, poisoning and procedural complications0/150/302/3040/102/3020/250/240/3150/177
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50/80/1460/30/1340/130/91/1510/90
Most frequent other events
Showing 10 of 41
Most frequent other events
Event3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/Sitagliptin (Baseline Through 104 Weeks)
NauseaGastrointestinal disorders5/156/3053/3044/1044/3023/252/2422/3159/177
GastritisGastrointestinal disorders0/151/3011/3042/104/3020/250/249/3157/177
VomitingGastrointestinal disorders2/154/3041/3042/1025/3021/251/2411/3153/177
DiarrhoeaGastrointestinal disorders0/155/3050/3041/1036/3024/252/2418/31515/177
NasopharyngitisInfections and infestations0/151/3043/3040/1048/3021/250/2447/31525/177
HyperglycaemiaMetabolism and nutrition disorders0/150/3030/3040/1038/3020/250/2449/31528/177
GastroenteritisInfections and infestations2/150/3012/3040/107/3021/250/246/3157/177
ConstipationGastrointestinal disorders1/150/3014/3040/1016/3023/250/244/3151/177
DyspepsiaGastrointestinal disorders0/151/3018/3041/1019/3023/251/2416/3154/177
Visual acuity reducedEye disorders0/150/301/3041/100/3020/250/240/3150/177

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/SitagliptinTotal
Mean52.81 ± 10.6652.56 ± 10.9553.66 ± 10.0255.38 ± 8.7154.35 ± 9.8154.70 ± 9.7256.51 ± 6.5653.75 ± 10.2754.91 ± 9.0554.09 ± 9.85
Sex: Female, Male
Sex: Female, Male(Participants)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/SitagliptinTotal
Female10221587168121516487643
Male58146313413915190559
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/SitagliptinTotal
Aboriginal and/or Torres Strait Islander0000000101
African1316012207950
Caucasian713157416291215891613
East Asian0650047055228188
Hispanic78546511466738251
Native American0000000101
West Asian (Indian sub-continent)002703001281197
Unknown or Not Reported0000000101
Region of Enrollment
Region of Enrollment(participants)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/SitagliptinTotal
United States917734831078046329
Taiwan011901803201273
Spain00100110011436
Russian Federation00210180017864
India002702900281296
France00120140012846
Mexico33325301063527151
Puerto Rico1212053010740
Canada00130110012642
Poland102002322231283
Romania12714048532
Germany0031031002815105
Korea, Republic of0527025023115105
Body Weight
Body Weight(kilograms)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/SitagliptinTotal
Mean85.09 ± 14.2586.56 ± 18.3386.67 ± 17.4589.48 ± 18.0686.22 ± 17.9988.84 ± 14.9881.94 ± 17.6785.97 ± 16.9187.07 ± 16.8686.38 ± 17.28
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m^2))3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/SitagliptinTotal
Mean31.02 ± 4.6931.45 ± 4.8831.40 ± 4.5733.89 ± 4.4431.15 ± 4.4432.53 ± 4.6131.06 ± 3.9431.02 ± 4.2031.37 ± 4.2531.27 ± 4.39
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/SitagliptinTotal
Mean7.95 ± 1.118.36 ± 1.048.12 ± 1.057.87 ± 0.628.19 ± 1.118.30 ± 1.347.82 ± 0.808.09 ± 1.098.10 ± 1.148.13 ± 1.09
Duration of Diabetes
Duration of Diabetes(years)3.0 mg LY21892652.0 mg LY21892651.5 mg LY21892651.0 mg LY21892650.75 mg LY21892650.5 mg LY21892650.25 mg LY2189265SitagliptinPlacebo/SitagliptinTotal
Mean6.79 ± 6.346.92 ± 5.126.95 ± 5.507.04 ± 4.577.34 ± 4.926.75 ± 3.996.74 ± 4.207.16 ± 4.896.96 ± 5.437.09 ± 5.12

1 further baseline measures are reported on the registry.

08

Study locations

99 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peoria, Arizona 85381, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85050, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucson, Arizona 85741, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fresno, California 93726, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mission Hills, California 91345, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Longmont, Colorado 80501, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Waterbury, Connecticut 06708, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hollywood, Florida 33021, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, Georgia 30606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30303, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Idaho Falls, Idaho 83404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Illinois 62704, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Metairie, Louisiana 70006, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Biddeford, Maine 04005, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ann Arbor, Michigan 48106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Southfield, Michigan 48075, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Clair Shores, Michigan 48081, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Billings, Montana 59101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rochester, New York 14607, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Syracuse, New York 13210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greensboro, North Carolina 27401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morehead City, North Carolina 28557, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winston-Salem, North Carolina 27103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Corvallis, Oregon 97330, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina 29412, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75230, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Georgetown, Texas 78626, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Federal Way, Washington 98003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tacoma, Washington 98405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T2H 2G4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winnipeg, Manitoba R3P 3P4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oakville, Ontario L6H 3P1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherbrooke, Quebec J1G 5K2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Corbeil-Essonnes, 91106, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    La Rochelle, 17019, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mantes La Jolie, 78200, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, F-34295, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Narbonne, 11108, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Mande, 94160, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Strasbourg, 67000, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toul, 54201, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Venissieux, 69200, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aschaffenburg, 63739, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bad Lauterberg, D-37431, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bad Staffelstein, D-96231, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bochum, D-44791, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Essen, 45355, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamburg, 21073, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hirschhorn, 69434, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mainz, D-55116, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Muenster, 48145, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neuwied, 56564, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pohlheim, D-35415, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rotenburg-Fulda, 36199, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ahmedabad, 380006, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangalore, 560038, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ghaziabad, 201 002, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kochin, 682026, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pune, 411005, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Goyang-Si, 410-719, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Incheon, 400-711, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seongnam-Si, 463-707, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 139-872, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sungnam-Si, 463-712, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aguascalientes, 20129, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chihuahua, 31238, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44600, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64461, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdynia, 81-557, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lodz, 93-319, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lublin, 20-954, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szczecin, 70-506, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wroclaw, 50-403, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manati, 00674, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00907, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baia Mare, 430123, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cluj-Napoca, 400006, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Timisoara, 300736, Romania
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arkhangelsk, 163045, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rostov-On-Don, 344022, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 193257, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dos Hermanas, 41014, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lleida, 25198, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Malaga, 29010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palma De Mallorca, 07010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pozuelo De Alarcon, 28223, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiayi City, 600, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung, 807, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung City, 40201, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 407, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tainan, 70403, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 100, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yung-Kang, Tainan, 710, Taiwan
09

References and documents

Publications

  • Sherman SI, Kloos RT, Tuttle RM, Pontecorvi A, Volzke H, Harper K, Vance C, Alston JT, Usborne AL, Sloop KW, Lakshmanan M. No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer. Diabet Med. 2018 Mar;35(3):381-385. doi: 10.1111/dme.13437. PubMed 28755389 ↗
  • Boustani MA, Pittman I 4th, Yu M, Thieu VT, Varnado OJ, Juneja R. Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged >/=65 and <65 years. Diabetes Obes Metab. 2016 Aug;18(8):820-8. doi: 10.1111/dom.12687. Epub 2016 Jun 7. PubMed 27161178 ↗
  • Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016 Apr;18(4):419-24. doi: 10.1111/dom.12624. Epub 2016 Feb 4. PubMed 26691396 ↗
  • Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015 Sep;17(9):849-58. doi: 10.1111/dom.12479. Epub 2015 May 20. PubMed 25912221 ↗
  • Skrivanek Z, Gaydos BL, Chien JY, Geiger MJ, Heathman MA, Berry S, Anderson JH, Forst T, Milicevic Z, Berry D. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014 Aug;16(8):748-56. doi: 10.1111/dom.12305. Epub 2014 May 22. PubMed 24762094 ↗
  • Spencer K, Colvin K, Braunecker B, Brackman M, Ripley J, Hines P, Skrivanek Z, Gaydos B, Geiger MJ. Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study. J Diabetes Sci Technol. 2012 Nov 1;6(6):1296-304. doi: 10.1177/193229681200600608. PubMed 23294774 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jun 2011 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 3 years 7 months after primary completion. A results delay was requested in Sep 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2008
First posted
Aug 14, 2008
Start
Aug 2008
Primary completionActual
Jun 2011
CompletionActual
Jul 2012
Results delay requested
Sep 20, 2011
Results first posted
Jan 28, 2015
Last update
Apr 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00734474
Collaborators
United BioSource, LLC, Tessella Inc., Berry Consultants
Responsible party
Sponsor
First posted
Aug 14, 2008
Start date
Aug 2008
Primary completion
Jun 2011
Completion
Jul 2012
Results posted
Jan 28, 2015
Last update
Apr 20, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study chair · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion